PET Using A Gallium-Labeled Prostate-Specific Membrane
Treatment of patients with biochemically recurrent prostate cancer is by disease location and extent. Major guidelines recommend computed tomography (CT); magnetic resonance imaging (MRI); and/or bone scintigraphy at biochemical recurrence. However, these guidelines acknowledge limited sensitivity at low prostate-specific antigen (PSA) levels. Novel positron emission tomography (PET) radiotracers; promise to overcome this limitation, most recently…